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Alterations in numerous tumor suppressor pathways 
involving oncogene overexpression and loss of tumor 
suppressors have been demonstrated to be crucial for 
tumorigenesis. Inactivation of the tumor suppressor 
p53 or components of the p53 pathway is common 
during tumor development. TP53 encodes a 
transcription factor that activates numerous genes that 
halt tumorigenesis [1]. Mutations in the TP53 gene 
occur in over 50% of human cancers [2]. Additionally, 
some tumors have an ablated p53 pathway yet lack 
TP53  mutations, suggesting alterations to other 
components in the p53 pathway occur during 
tumorigenesis [2]. One key component of the p53 
pathway is Mdm2.  This gene is amplified or 
overexpressed in a large number of human cancers that 
retain wild type TP53 [3, 4]. Mdm2 encodes an E3 
ubiquitin ligase that negatively regulates p53 protein 
stability and transcriptional activity [5]. These data 
demonstrate that decreased p53 activity, resulting from 
mutations in the TP53 gene or alterations in Mdm2 
significantly impact tumor development. Data derived 
from mouse studies have shown that a fine tuned 
regulation of Mdm2 levels is necessary to maintain 
proper p53 homeostasis and therefore p53-mediated 
tumor suppression, which suggests that modest changes 
in Mdm2 levels may have an important impact on 
tumor development.  
  Recently, a functional T to G single nucleotide 
polymorphism (SNP) in the human Mdm2 gene 
(SNP309G) has been identified [6]. This SNP enhances 
the binding of the transcription factor Sp1 to the Mdm2 
promoter which in turn results in increased Mdm2 
mRNA levels and thereby lower p53 levels. Of 
importance to cancer development, the Mdm2
SNP309G 
allele has been associated with an increased cancer risk 
in some human tumors that express wild type p53 [7-
9]. However, some reports have failed to show a 
correlation between the Mdm2
SNP309G allele and cancer 
risk [10, 11].  The impact that Mdm2
SNP309G has on 
cancer risk is supported by the findings that patients 
diagnosed with Li-Fraumeni syndrome (LFS), a 
syndrome resulting from inherited germline mutations 
in p53, that are also homozygous for the Mdm2
SNP309G 
allele develop tumors significantly earlier than patients 
with LFS lacking this polymorphism [6, 12].  These 
data suggest that increased Mdm2 levels resulting from 
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ABSTRACT: 
A T-to-G germline single nucleotide polymorphism in the promoter region of MDM2 
(SNP309) has been reported to markedly accelerate tumor formation in humans 
suggesting that it may represent a powerful cancer predisposing allele. Since its first 
description in 2004, a large number of retrospective analyses involving a wide variety 
of human malignancies have been reported, showing conflicting results regarding the 
impact of Mdm2
SNP309 status on cancer risk and response to cancer therapy. Here, we 
appraise the available information on the effect of Mdm2
SNP309  in lymphoma and 
leukemia and discuss the factors that likely account for the conflicting results 
observed in the studies reported to date.  
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the presence of the Mdm2
SNP309G  allele may further 
down modulate an already deficient p53 pathway.  
Relatively little is known regarding the impact that 
subtle genetic modifiers have on tumorigenesis. 
Examination of large cohorts of patients carrying the 
Mdm2
SNP309 allele suggests that subtle changes to the 
p53 pathway may have a pronounced impact on 
tumorigenesis. Several caveats hamper a proper 
interpretation of such clinical studies, including the fact 
that they are retrospective in nature, with all the biases 
associated with such type of analyses, and the fact that 
they involve patients from different ethnic 
backgrounds, therefore not accounting for the potential 
impact that other gene modifiers (e.g. other SNPs) may 
have on the p53 pathway. Certainly an unbiased 
prospective analysis of patients with cancer is 
warranted to definitely delineate the impact of the 
Mdm2
SNP309 allele on cancer risk and response to 
therapy. The development of mouse models mimicking 
the human Mdm2
SNP309 allele may advance 
significantly our understanding of the impact that 
subtle genetic differences may have in the regulation of 
the p53 pathway. Alterations in the p53 pathway have 
been reported in an important fraction of patients with 
leukemia or lymphoma. In this paper we appraise the 
available information on the impact of the Mdm2
SNP309 
allele in lymphomagenesis and leukemogenesis. 
 
IMPACT OF THE MDM2
SNP309 ALLELE ON 
LEUKEMOGENESIS 
 
The tumor suppressor TP53 is mutated in more than 
50% of all human solid tumors and in approximately 
30% of patients with leukemia. Notably, p53 has been 
shown to play a critical role in hematopoiesis. 
Fluctuations in p53 levels and activity result in drastic 
consequences to the hematopoietic compartment, as 
demonstrated in mouse models with haploinsufficiency 
of its negative regulators Mdm2 and Mdm4 [13, 14]. 
The  Mdm2
SNP309 allele has been associated with 
attenuation of p53 activity and early onset of human 
cancers [6]. Extrapolation of these results to examine 
the impact of the Mdm2
SNP309 allele on leukemogenesis 
has rendered multiple studies reporting conflicting 
results. Three major types of leukemia, chronic 
lymphocytic leukemia (CLL), childhood acute 
lymphoblastic leukemia (ALL) and acute myeloid 
leukemia (AML) have been primarily investigated with 
regards to Mdm2
SNP309 status and outcome. 
 
CLL is the most frequent leukemia in the western 
hemisphere with an incidence rate of 4/100000. The 
incidence rates in men are nearly twice as high as in 
women. CLL is characterized by the accumulation of 
mature CD5
+, CD19
+ B-lymphocytes in the 
hematopoietic system [15, 16]. Several prognostic 
factors have been linked to a poor prognosis in patients 
with CLL. Among them, the presence of unmutated 
immunoglobulin  (Ig)-VH gene and the expression of 
CD38 and Zap70 are the ones that have shown more 
robust results as risk factors in clinical trials [15]. p53 
plays a critical role in regulating tumor growth and p53 
status has been shown to be critical for survival of 
patients with CLL. p53 inactivation has been 
documented in patients with CLL primarily due to 
17p13 deletion and point mutations. Patients with CLL 
exhibit a deletion of 17p13 in approximately 5–7% in 
early stage disease and in 25–40% in advanced and/or 
refractory disease [17]. Patients with the 17p13 
chromosomal abnormality exhibit very aggressive 
disease, poor response to chemotherapy, and a very 
poor prognosis [18]. In addition, TP53 mutations can 
be detected in up to 20-30% of patients with CLL [17], 
which implies that, in the remaining cases, possibly 
other alterations in the p53 pathway may be involved in 
CLL. Interestingly, overexpression of Mdm2, a major 
p53 regulator has been shown in 28% of patients with 
B-CLL. The well documented functional association of 
Mdm2
SNP309  in human tumors, and the important 
prognostic role of p53 in CLL, provides the rationale 
for studying the prognostic and predictive implications 
of Mdm2
SNP309in patients with CLL.  
The very first study investigating the impact of 
Mdm2
SNP309  on leukemogenesis did not find any 
difference in the mean age at diagnosis between the 
different  Mdm2
SNP309  genotype subsets [19]. In 
addition, the authors did not find any significant 
association between the Mdm2
SNP309 and the p53 codon 
72 arginine-to-proline (p53
R72P) polymorphisms or 
other prognostic markers such as the mutational status 
of the VH gene, CD38 expression and Zap70 
expression. However, the limited cohort size in this 
study (n=83) precluded a robust statistical analysis. In 
contrast, another study reported that carrying the 
Mdm2
SNP309G allele was associated with a decreased 
risk of leukemia in patients of Chinese origin [20]. 
However, once again a small cohort size and clubbing 
together different kinds of leukemia patients made the 
results difficult to interpret. 
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In the first major systematic study, Gryschenko et 
al. analyzed two different cohorts of patients (n=140 
and n=111, respectively) and showed that occurrence 
of homozygous (G/G) Mdm2
SNP309 did not predispose 
to CLL [21]. However, patients that were either 
heterozygous (T/G) or homozygous (G/G) at the 
Mdm2
SNP309 loci had significantly shortened treatment 
free survival (TFS) and overall survival (OS) in 
comparison to patients with the (T/T) genotype. 
Multivariate analysis also identified Mdm2
SNP309 as an 
independent prognostic factor for TFS and OS. In 
contrast, an unbiased analysis of a large cohort of 
patients with CLL (n=418) did not detect any 
association of Mdm2
SNP309 and time to first treatment 
and overall survival [22]. Likewise, no apparent 
correlation between the different Mdm2
SNP309 
genotypes and Binet stage or IgVH mutational status 
was identified. Another study involving an even larger 
cohort of patients (n=617) also confirmed these results 
and could not detect any correlation between 
Mdm2
SNP309  and the other established prognostic 
markers in CLL [23]. Carrying the Mdm2
SNP309 allele 
did not impact OS.  
A recent study from Sweden involving 210 patients 
with CLL followed for over 19 years reported that the 
OS of patients with at least one Mdm2
SNP309G allele was 
significantly shorter than that of patients with two 
Mdm2
SNP309T alleles [24]. However, the age of onset of 
B-CLL was similar between the two genotypes. The 
presence of an Mdm2
SNP309G allele in combination with 
TP53 mutations or unmutated IgVH gene status resulted 
in an additional risk. This study supported the claim by 
Gryschenko  et al. of Mdm2
SNP309  as a prognostic 
marker in concert with TP53 mutations and unmutated 
IgVH status. However, these data are in conflict with 
Kaderi et al and Zenz et al, which could be explained 
by the difference in patient cohort composition in these 
studies. Differences in the number of patients with 
unmutated  IgVH gene and a higher proportion of 
advanced Binet stage patients may have accounted for 
such discrepant results. Additionally, unlike 
Gryschenko  et al., the authors did not observe any 
reduction in TFS in patients carrying two Mdm2
SNP309T 
versus two Mdm2
SNP309G alleles, suggesting that 
Mdm2
SNP309 mainly influences the outcome of therapy. 
This contention is intriguing particularly in light of 
data reported by Saddler et al. showing that treatment 
with nutlin-3a, a drug that disrupts the interaction 
between Mdm2 and p53, efficiently induces apoptosis 
of B-CLL cells in vitro [25]. Similar results were also 
reported by Seyfried et al [26]. Moreover, a recent 
report analyzing a small cohort of patients with CLL 
(n=75) in conjunction with studies involving the TCL1 
mouse model, an established mouse model of B-CLL, 
showed that miR34a, a p53 downstream pro-apoptotic 





with wild type p53 have a lower expression of miR34a 
and lower TFS. In aggregate, these data suggest that 
Mdm2
SNP309T/G or Mdm2
SNP309G/G genotypes possibly 
alleviate the sensitivity to chemotherapy regimens by 
suppressing the p53 pro-apoptotic activity.  
In addition to CLL, studies have also focused on 
ALL, a leading cause of childhood cancer. ALL 
accounts for 25-30% of all diagnoses in infants below 1 
year of age. p53 mutations are rare in childhood ALL. 
However, components
  of the p53 pathway are 
frequently found mutated in ALL [28]. Indeed, deletion
 
or transcriptional silencing of p14
ARF is frequent in
 
ALL, while Mdm2 overexpression or silencing of the 
p53
 transcriptional target p21
CIP1 has been reported in 
approximately 50% of patients with ALL and linked 
with worse prognosis [28]. Analyses of 284 samples 
obtained from children with ALL revealed that the 
presence of the Mdm2
SNP309G allele significantly 
decreased the age of onset for ALL in Caucasian and 
African-American patients but not Hispanic patients 
[29]. These findings suggest an ethnic specific effect of 
Mdm2
SNP309 in ALL, which has also been reported in 
patients with solid tumors. A separate study of 114 
children with ALL however could not confirm any 
statistical correlation between Mdm2
SNP309 and age of 
onset of ALL [30]. Nonetheless, a sex specific effect of 
the polymorphism on earlier disease onset was 
identified. Females that are homozygous carriers of the 
Mdm2
SNP309G allele had a significantly earlier disease 
onset compared to those carrying two Mdm2
SNP309T 
alleles. While estrogen has earlier been shown to affect 
Mdm2
SNP309  activity, this observation is quite 
interesting given the fact that children with ALL have 
negligible estrogen activity. While it could be 
hypothesized that fetal estrogen exposure may impact 
postnatal Mdm2 activity, a more detailed investigation 
of a larger cohort of patients is required to confirm this 
hypothesis.  
Several studies have addressed the possibility of an 
association between Mdm2
SNP309 and the development 
of therapy related AML. Therapy related AML arises 
as a consequence of prior cytotoxic therapy and as 
many as 10% of patients treated for a first cancer 
develop this potentially fatal secondary malignancy. 
Examination of two cohorts of patients (n=80 and  
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n=91) who developed treatment related AML 
following chemo/radiotherapy regimens for another 
tumor type did not reveal any significant association 
between Mdm2
SNP309 and the risk of treatment related 
AML [31]. However, an interactive effect between 
Mdm2
SNP309  and the p53
R72P  SNP towards increased 
risk of AML was observed in patients previously 
treated with chemotherapy. Nevertheless, analysis of 
data sets from a large group of patients with AML 
(n=404 and 816) revealed a modest increase in risk of 
de novo AML in patients with an Mdm2
SNP309G 
background. In agreement with the latter, a study by 
Xiong et al., reported a 3.52-fold increase in AML risk 
but no association of Mdm2
SNP309 with age of onset of 
AML in a cohort of 231 patients with AML [32]. A 
recent study reported similar results on 575 children 
with AML treated on three Children’s Oncology Group 
protocols (CCG 2941/2961/AAML 03P1). This study 
revealed that patients carrying two copies of the 
Mdm2
SNP309G allele had an increased susceptibility to 
AML [33]. However, unlike CLL [21], Mdm2
SNP309 
status had no apparent effect on treatment outcome in 
AML.  
In conclusion, although these studies present 
conflicting results, they appear to agree in that the 
presence of an Mdm2
SNP309G  allele correlates with 
earlier onset of childhood ALL in an ethnicity and sex 
specific manner but may not correlate with incidence 
or onset of B-CLL. Additionally, the Mdm2
SNP309G/G 
genotype increases the risk of de novo AML. The 
presence of the Mdm2
SNP309G  allele either in the 
heterozygous or the homozygous state also 
significantly impacts the overall survival of patients 
with CLL or AML. There are several aspects that 
preclude a clear interpretation of results from these 
studies. Mdm2
SNP309 is a weak modifier of p53 activity 
and its effect is influenced by sex, age, gender, 
ethnicity and other environmental factors [8]. 
Furthermore, CLL, ALL and AML are genetically 
heterogeneous diseases with varied outcomes in 
different individuals depending on factors such as age 
at diagnosis, performance status, and the presence of 
specific chromosomal abnormalities. Furthermore, 
there are multiple SNPs in the p53 pathway that could 
alter p53 function. In fact, the polymorphic p53
R72P 
protein may likewise influence the effect of the 
Mdm2
SNP309
  allele. Some of the above studies have 
taken into consideration the potential interplay between 
these two SNPs. However, a comprehensive study 
validating such interplay is lacking. Additionally, 
mutations or defects in p53 or its modulators such as 
ATM, Mdm4, or p14
ARF may likewise affect p53 
function.  A multivariate, detailed analysis (meta-
analysis) of a larger cohort of a more biologically 
homogenous population will be more informative in 
this regard.  
Given these complexities, the examination of 
Mdm2
SNP309 status in isolation as a prognostic marker 
for CLL, ALL or AML and for the intent of designing 
individualized treatment regimens may not be of great 
clinical impact. However, a synergistic role of the 
Mdm2
SNP309  allele with other prognostic markers is 
likely and it may predict for response in patients 
receiving p53-directed therapy (e.g. nutlin-3a).  
 
IMPACT OF THE MDM2
SNP309 ALLELE ON 
LYMPHOMAGENESIS 
 
A series of small scale retrospective studies have 
also been undertaken to address the impact of 
Mdm2
SNP309G on lymphomagenesis [8, 34-36]. The 
initial description of the role that Mdm2
SNP309G has on 
diffuse large B-cell lymphomagenesis (DLBCL) was 
reported by Bond and colleagues [8].  In this study, the 
authors demonstrated that women (under the average 
age of 51, and therefore considered to be 
premenopausal), who self-identified themselves as 
being of Ashkenazi Jewish decent, carrying the 
Mdm2
SNP309G allele were more likely to develop 
DLBCL than young women harboring two 
Mdm2
SNP309T alleles. Specifically, women harboring 
two Mdm2
SNP309G alleles were diagnosed with DLCBL 
13-years earlier than women who carried two 
Mdm2
SNP309T alleles,  with an average age of 55 years 
(ranging from 21 to 87 years) and 68 years (ranging 
from 55 to 78 years), respectively.  In fact, 49% of 
women carrying Mdm2
SNP309G were diagnosed with 
DLBCL before the age of 51.  This is in direct contrast 
to premenopausal women carrying Mdm2
SNP309T/T, as 
no individual younger than 51 years of age presented 
with DLBCL in this study.  It is important to note, that 
the significant impact of Mdm2
SNP309G on DLBCL 
development in women of Ashkenazi Jewish descent 
was lost when patients were diagnosed after the age of 
51 (considered menopausal).  The fact that young 
premenopausal women harboring the G nucleotide 
were more likely to develop DLBCL led the authors to 
speculate that hormone specific factors might influence 
this early tumor phenotype.  This notion is supported 
by several observations. First, women exposed to 
exogenous estrogen have an altered risk in DLBCL 
development [37]. Secondly, Mdm2 levels are  
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regulated by estrogen signaling as the Mdm2 promoter 
possesses an estrogen response element (ERE) [38].   
Interestingly, this ERE lies in a region just upstream of 
the Mdm2
SNP309 polymorphism. Third, the 
Mdm2
SNP309G allele results in an increased affinity for 
the transcription factor Sp1 [6]. Several studies have 
demonstrated that Sp1 activity is further stimulated 
upon its interaction with hormone receptors such as the 
estrogen receptor [39]. Taken together, these findings 
suggest that Mdm2
SNP309G may regulate DLBCL 
development in a gender-specific mode.  
A second report on woman of European Caucasian 
descent with DLBCL, suggested the Mdm2
SNP309 
polymorphism has no impact on age of tumor onset, 
even in premenopausal women (under the age 51) [36]. 
These results are at variance with those reported by 
Bond et al, as Bittenbring and colleagues were unable 
to detect a significant impact on DLBCL formation in 
young women carrying two Mdm2
SNP309G alleles. These 
differing results highlight the complexity of 
determining a functional outcome of an individual SNP 
on a specific tumor type, especially a SNP in a 
regulatory element such as Mdm2
SNP309.  In this report, 
Bittenbring and colleagues suggest a potential cause for 
these discordant observations may be due to ethnicity 
differences between the two studies.  This is a 
potentially plausible explanation as Ashkenazi Jews are 
more genetically isolated as compared to individuals 
from Europe as a whole.  Indeed, while approximately 
25% of Ashkenazi Jews harbor two Mdm2
SNP309G 
alleles only 14% of central European women carried 
this allele.  This increased prevalence in the 
Mdm2
SNP309G in the Ashkenazi Jewish community may 
afford an invaluable opportunity to identify individuals 
carrying this SNP, and therefore, to ascertain the 
impact of such genetic variant in lymphomagenesis. 
Additionally, the differing outcome may be a 
consequence of a low number of Mdm2
SNP309G/G 
premenopausal samples used by Bittenbring et al (20 
premenopausal female patient samples). This fact 
would warrant that a more exhaustive study be 
performed.  Alternatively and of much more interest, 
these different results may suggest that other currently 
undescribed genetic modifiers (especially in the p53 
pathway) may also influence the functionality of the 
Mdm2
SNP309G allele; such as the recently identified 
SNPs in Mdm4, HAUSP, and/or p53 [40]. This notion 
is quite plausible as it has been noted that Ashkenazi 
Jews who are isolated genetically, may harbor 
additional low penetrant modifiers that could 
potentially either detract or augment the function of 
Mdm2
SNP309G. The effect of such compounding 
polymorphisms on the functionality of Mdm2
SNP309G is 
unknown and may be different in genetically 





To definitely ascertain the impact of the 
Mdm2
SNP309 allele on leukemogenesis and 
lymphomagenesis, prospective analyses of large 
cohorts of patients are warranted. Given the inherent 
biases of all the retrospective studies above-described, 
which undoubtedly account for the conflicting results, 
the development of animal models carrying the 
Mdm2
SNP309 allele could certainly be of great interest. 
Our laboratory has generated two complementary 
humanized  Mdm2




SNP309T) in order to examine the direct impact 
of this SNP on tumor development [41]. Using these 
mice we have shown that harboring two Mdm2
SNP309G 
alleles increases Mdm2 levels and subsequently 
decreases p53 as compared to Mdm2
SNP309T/T  mice. 
Furthermore, Mdm2
SNP309G/G mice have an attenuated 
p53 response following treatment with ionizing 
radiation. More importantly, Mdm2
SNP309G/G  mice 
(either carrying a p53 germline mutation or not) rapidly 
develop tumors resulting in shorter survival as 
compared to Mdm2
SNP309T/T mice. Crossing these mice 
with the previously reported TCL1 transgenic mouse 
[42], an established B-CLL mouse model, or the BCL6 
transgenic mouse, an established model that 
recapitulated human DLBCL, may provide suitable 
model systems to investigate the deregulation of the 
p53 pathway induced by the Mdm2
SNP309 allele and its 
impact on leukemogenesis and lymphomagenesis while 
prospective studies in patients with these hematological 
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